Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.

Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.
复制标题

DOI:
10.1021/acs.jnatprod.0c00613
复制
发表时间:
2020-08-28
影响因子:
5.1
通讯作者:
Bachmann, Andre S.
Bachmann, Andre S.
中科院分区:
生物学2区
文献类型:
--
作者:
Schultz, Chad R.;Gruhlke, Martin C. H.;Slusarenko, Alan J.;Bachmann, Andre S.

文献摘要

参考文献

被引文献

相似文献

大蒜素是大蒜中的一种活性硫物质。神经母细胞瘤(NB)是一种早期儿童癌症,起源于发育中的外周神经系统。鸟氨酸脱羧酶(ODC)是多胺生物合成中的限速酶,多胺是促进NB和其他c-MYC/MYCN驱动的癌症中的细胞增殖的肿瘤素。c-MYC和MYCN都直接反式激活E-box基因ODC 1,这是一种经过验证的抗癌药物靶标。我们确定大蒜素作为一个有效的ODC抑制剂,在特定的放射性体外测定使用纯化的人ODC。在相同的体外试验条件下,大蒜素的效力(IC 50 = 11 nM)比DFMO(IC 50 = 252 μM)高约23000倍。ODC是每个单体具有12个半胱氨酸的同源二聚体,并且大蒜素可逆地S-硫代烯丙基化半胱氨酸。在活跃增殖的人NB细胞中,大蒜素抑制ODC酶活性,降低细胞多胺水平,抑制细胞增殖(IC 50 9-19 μM),并诱导凋亡。天然产物大蒜素是一种新的ODC抑制剂,可以与其他抗癌治疗联合使用,后者可能比通常的剂量低,以实现药物协同作用,具有良好的预后和减少的不良反应。
The natural product allicin is a reactive sulfur species (RSS) from garlic (Allium sativum L.). Neuroblastoma (NB) is an early childhood cancer arising from the developing peripheral nervous system. Ornithine decarboxylase (ODC) is a rate-limiting enzyme in the biosynthesis of polyamines, which are oncometabolites that contribute to cell proliferation in NB and other c-MYC/MYCN-driven cancers. Both c-MYC and MYCN directly transactivate the E-box gene ODC1, a validated anticancer drug target. We identified allicin as a potent ODC inhibitor in a specific radioactive in vitro assay using purified human ODC. Allicin was ~23000-fold more potent (IC50 = 11 nM) than DFMO (IC50 = 252 μM), under identical in vitro assay conditions. ODC is a homodimer with 12 cysteines per monomer, and allicin reversibly S-thioallylates cysteines. In actively proliferating human NB cells allicin inhibited ODC enzyme activity, reduced cellular polyamine levels, inhibited cell proliferation (IC50 9–19 μM), and induced apoptosis. The natural product allicin is a new ODC inhibitor and could be developed for use in conjunction with other anticancer treatments, the latter perhaps at a lower than usual dosage, to achieve drug synergism with good prognosis and reduced adverse effects.
DOI: 10.1111/j.1529-8019.2008.00215.x
发表时间: 2008-09-01
影响因子: 3.6
作者:
Blume-Peytavi, Ulrike;Hahn, Susanne
通讯作者: Hahn, Susanne
DOI: 10.1093/cid/cis886
发表时间: 2013-01-15
影响因子: 11.8
作者:
Alirol, Emilie;Schrumpf, David;Chappuis, Francois
通讯作者: Chappuis, Francois
DOI: 10.1038/360355a0
发表时间: 1992-11-26
期刊: NATURE
影响因子: 64.8
作者:
AUVINEN, M;PAASINEN, A;HOLTTA, E
通讯作者: HOLTTA, E
DOI: 10.1073/pnas.0901982106
发表时间: 2009-04-21
影响因子: 11.1
作者:
Clerc, Jerome;Groll, Michael;Kaiser, Markus
通讯作者: Kaiser, Markus
多胺代谢和癌症:治疗,挑战和机遇。
DOI: 10.1038/s41568-018-0050-3
发表时间: 2018-11
期刊: Nature reviews. Cancer
影响因子: --
作者:
Casero RA Jr;Murray Stewart T;Pegg AE
通讯作者: Pegg AE